EFFECT OF THYMOQUINONE ON INTERLEUKIN-8, FEV1, AND COPD ASSESSMENT TEST SCORE IN STABLE CHRONIC OBSTRUCTIVE LUNG DISEASE

Y. Sutanto, Levana Kasumadewi, S. Suradi, A. Setijadi, Hendra Kurniawan
{"title":"EFFECT OF THYMOQUINONE ON INTERLEUKIN-8, FEV1, AND COPD ASSESSMENT TEST SCORE IN STABLE CHRONIC OBSTRUCTIVE LUNG DISEASE","authors":"Y. Sutanto, Levana Kasumadewi, S. Suradi, A. Setijadi, Hendra Kurniawan","doi":"10.26911/the7thicph-FP.05.13","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background: Chronic obstructive pulmonary disease (COPD), a persistent airway obstruction, is caused by continuous exposure to harmful particles or irritants. Airway inflammation contributes the pathogenesis of COPD. Thymoquinone, has an anti-inflammatory effect. This study aimed to examine the effect of thymoquinone on interleukin-8 (IL-8) level, percentage of FEV1, and COPD assessment test score (CAT) in stable chronic obstructive lung disease. Subjects and Method: A quasi-experiment with pretest and posttest control group was conducted at the outpatient pulmonology unit, Dr. Moewardi, Surakarta, Central Java, from June to August 2019. A sample of 40 patients diagnosed with stable COPD was selected and allocated into two groups: (1) 20 patients treated with a combination of standard therapy and thymoquinone oil capsules 500 mg/ day; and (2) 20 patients treated with standard therapy. The dependent variables were IL-8 level, FEV1, and COPD assessment test score (CAT). The independent variables were treatment status. The data were analyzed by the paired-t-test. Results: The level of IL-8 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 14.35; SD= 3.95) than before treatment (Mean= 19.62; SD= 12.14), and it was not statistically significant (p= 0.052). The percentage of FEV1 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 42.36; SD= 14.43) than before treatment (Mean= 42.56; SD= 16.09), and it was not statistically significant (p= 0.943). The CAT score was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 13.70; SD= 4.24) than before treatment (Mean= 13.70; SD= 4.24) than before treatment (Mean= 18.65; SD= 5.92), and it was statistically significant. Conclusion: Chronic obstructive pulmonary disease assessment test (CAT) score significantly decreases with the treatment combination of standard COPD therapy and thymoquinone oil capsules 500 mg/ day. Keywords: Thymoquinone, stable COPD, IL-8, FEV1, CAT score Correspondence: Yusup Subagio Sutanto. Department of Pulmonology and Respiratory Medicine, Dr. Moewardi Hospital Surakarta. Jl. Kolonel Soetarto No. 132 Surakarta, Central Java. Email: dr_yusupsubagio@yahoo.com. Mobile: +62811284165. DOI: https://doi.org/10.26911/the7thicph.05.34","PeriodicalId":130555,"journal":{"name":"Childhood Stunting, Wasting, and Obesity, as the Critical Global Health Issues: Forging Cross-Sectoral Solutions","volume":"80 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Childhood Stunting, Wasting, and Obesity, as the Critical Global Health Issues: Forging Cross-Sectoral Solutions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26911/the7thicph-FP.05.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

ABSTRACT Background: Chronic obstructive pulmonary disease (COPD), a persistent airway obstruction, is caused by continuous exposure to harmful particles or irritants. Airway inflammation contributes the pathogenesis of COPD. Thymoquinone, has an anti-inflammatory effect. This study aimed to examine the effect of thymoquinone on interleukin-8 (IL-8) level, percentage of FEV1, and COPD assessment test score (CAT) in stable chronic obstructive lung disease. Subjects and Method: A quasi-experiment with pretest and posttest control group was conducted at the outpatient pulmonology unit, Dr. Moewardi, Surakarta, Central Java, from June to August 2019. A sample of 40 patients diagnosed with stable COPD was selected and allocated into two groups: (1) 20 patients treated with a combination of standard therapy and thymoquinone oil capsules 500 mg/ day; and (2) 20 patients treated with standard therapy. The dependent variables were IL-8 level, FEV1, and COPD assessment test score (CAT). The independent variables were treatment status. The data were analyzed by the paired-t-test. Results: The level of IL-8 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 14.35; SD= 3.95) than before treatment (Mean= 19.62; SD= 12.14), and it was not statistically significant (p= 0.052). The percentage of FEV1 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 42.36; SD= 14.43) than before treatment (Mean= 42.56; SD= 16.09), and it was not statistically significant (p= 0.943). The CAT score was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 13.70; SD= 4.24) than before treatment (Mean= 13.70; SD= 4.24) than before treatment (Mean= 18.65; SD= 5.92), and it was statistically significant. Conclusion: Chronic obstructive pulmonary disease assessment test (CAT) score significantly decreases with the treatment combination of standard COPD therapy and thymoquinone oil capsules 500 mg/ day. Keywords: Thymoquinone, stable COPD, IL-8, FEV1, CAT score Correspondence: Yusup Subagio Sutanto. Department of Pulmonology and Respiratory Medicine, Dr. Moewardi Hospital Surakarta. Jl. Kolonel Soetarto No. 132 Surakarta, Central Java. Email: dr_yusupsubagio@yahoo.com. Mobile: +62811284165. DOI: https://doi.org/10.26911/the7thicph.05.34
百里醌对稳定型慢性阻塞性肺疾病患者白细胞介素-8、fev1及copd评估测试评分的影响
背景:慢性阻塞性肺疾病(COPD)是一种持续性气道阻塞,是由持续暴露于有害颗粒或刺激物引起的。气道炎症参与COPD的发病机制。百里醌有消炎作用。本研究旨在探讨百里醌对稳定型慢性阻塞性肺疾病患者白细胞介素-8 (IL-8)水平、FEV1百分比和COPD评估测试评分(CAT)的影响。对象与方法:于2019年6 - 8月在中爪哇省苏拉卡塔市Moewardi医生门诊肺科进行准实验,分为前测和后测对照组。选择40例诊断为稳定期COPD的患者,将其分为两组:(1)20例患者采用标准治疗联合百里醌油胶囊500 mg/ d治疗;(2)标准治疗20例。因变量为IL-8水平、FEV1、COPD评估测试评分(CAT)。自变量为治疗状态。数据采用配对t检验分析。结果:标准治疗联合百里醌油胶囊500 mg/ d治疗后IL-8水平降低(平均= 14.35;SD= 3.95)较治疗前(Mean= 19.62;SD= 12.14),差异无统计学意义(p= 0.052)。标准疗法联合百里醌油胶囊500 mg/ d治疗后,FEV1百分比较低(平均= 42.36;SD= 14.43)较治疗前(Mean= 42.56;SD= 16.09),差异无统计学意义(p= 0.943)。标准治疗联合百里醌油胶囊500 mg/ d治疗后CAT评分较低(Mean= 13.70;SD= 4.24)较治疗前(Mean= 13.70;SD= 4.24)较治疗前(Mean= 18.65;SD= 5.92),差异有统计学意义。结论:慢性阻塞性肺疾病评估试验(CAT)评分在标准COPD治疗联合百里醌油胶囊500 mg/ d治疗组显著降低。关键词:百里醌,稳定期COPD, IL-8, FEV1, CAT评分苏拉塔Moewardi医生医院肺病和呼吸内科。杰。苏塔托上校,中爪哇,苏拉卡塔132号。电子邮件:dr_yusupsubagio@yahoo.com。手机:+ 62811284165。DOI: https://doi.org/10.26911/the7thicph.05.34
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信